STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
1 . A liquid pharmaceutical formulation comprising more than about 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof, comprising a light chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9, and a heavy chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, wherein the formulation does not contain the excipient NaCl.
2 . The formulation of claim 1 , wherein the formulation comprises more than about 30 mg of the polyol.
3 . The formulation of claim 1 , wherein the formulation comprises more than about 40 mg of the polyol.
4 . The formulation of claim 1 , wherein the formulation comprises about 40-45 mg of the polyol.
5 . The formulation of claim 1 , wherein the polyol is a sugar alcohol.
6 . The formulation of claim 5 , wherein the sugar alcohol is mannitol or sorbitol.
7 . The formulation of claim 1 , wherein the human antibody is a human IgG1 kappa antibody.
8 . The formulation of claim 1 , wherein the light chain of the human antibody further comprises a CDR2 domain comprising an amino acid sequence set forth as SEQ ID NO: 5 and a CDR1 domain comprising an amino acid sequence set forth as SEQ ID NO: 7, and/or the heavy chain of the human antibody comprises a CDR2 domain comprising an amino acid sequence set forth as SEQ ID NO: 6 and a CDR1 domain comprising an amino acid sequence set forth as SEQ ID NO: 8.
9 . The formulation of claim 1 , wherein the light chain of the human antibody comprises the amino acid sequence set forth as SEQ ID NO: 1 and the heavy chain of the human antibody comprises the amino acid sequence set forth as SEQ ID NO: 2.
10 . The formulation of claim 1 , wherein the antibody is adalimumab.
11 . A liquid pharmaceutical formulation having a pH of about 5.0 to 6.4 and comprising at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof, comprising a light chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 3 and a heavy chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 4, wherein the formulation does not contain NaCl and has a turbidity of less than about 60 NTU after a standard 24 hour stir-stress assay.
12 . A liquid pharmaceutical formulation having a pH of about 5.0 to 6.4 and comprising at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof, comprising a light chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 3 and a heavy chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 4, wherein the formulation does not contain NaCl and has a turbidity of less than about 100 NTU after a standard 48 hour stir-stress assay.
13 . A liquid pharmaceutical formulation having a pH of about 5.0 to 6.4 and comprising at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof, comprising a light chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 3 and a heavy chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 4, wherein the formulation does not contain NaCl and has a turbidity of less than about 40 NTU after 3 months storage at 5° C., 25° C., or 40° C.
14 . The formulation of any one of claims 11 - 13 , further comprising more than about 20 mg of a polyol.
15 . The formulation of any one of claims 11 - 13 , further comprising more than about 30 mg of the polyol.
16 . The formulation of any one of claims 11 - 13 , further comprising more than about 40 mg of the polyol.
17 . The formulation of any one of claims 11 - 13 , further comprising about 40-45 mg of the polyol.
18 . The formulation of claim 14 , wherein the polyol is a sugar alcohol.
19 . The formulation of claim 18 , wherein the sugar alcohol is mannitol or sorbitol.
20 . The formulation of any one of claims 11 - 13 , wherein the pH is either about 5.0-5.4 or about 5.8-6.4
21 . The formulation of any one of claims 11 - 13 , having less than about 1% aggregate protein.
22 . The formulation of any one of claims 11 - 13 , wherein the human antibody is a human IgG1 kappa antibody.
23 . The formulation of any one of claims 11 - 13 , wherein the light chain of the human antibody further comprises a CDR2 domain comprising an amino acid sequence set forth as SEQ ID NO: 5 and a CDR1 domain comprising an amino acid sequence set forth as SEQ ID NO: 7, and/or the heavy chain of the human antibody comprises a CDR2 domain comprising an amino acid sequence set forth as SEQ ID NO: 6 and a CDR1 domain comprising an amino acid sequence set forth as SEQ ID NO: 8.
24 . The formulation of any one of claims 11 - 13 , wherein the light chain of the human antibody comprises the amino acid sequence set forth as SEQ ID NO: 1 and the heavy chain of the human antibody comprises the amino acid sequence set forth as SEQ ID NO: 2.
25 . The formulation of any one of claims 11 - 13 , wherein the antibody is adalimumab.
26 . A liquid pharmaceutical formulation comprising
at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof, comprising a light chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 3 and a heavy chain comprising a CDR3 domain comprising an amino acid sequence set forth as SEQ ID NO: 4;
more than about 20 mg/mL of a sugar alcohol;
about 0.1-2.0 mg/mL of a surfactant;
about 1.15-1.45 mg/mL of citric acid*H2O;
about 0.2-0.4 mg/mL of sodium citrate dehydrate;
about 1.35-1.75 mg/mL of Na2HPO4*2H2O;
about 0.75-0.95 mg/mL of NaH2PO4*2H2O,
wherein the formulation has a pH of about 4.7 to 6.5 and does not comprise NaCl.
27 . The formulation of claim 26 , wherein the sugar alcohol is either mannitol or sorbitol.
28 . The formulation of claim 27 , comprising about 40-45 mg/mL of either mannitol or sorbitol.
29 . The formulation of claim 26 , wherein the surfactant is polysorbate 80.
30 . The formulation of claim 29 , comprising about 1 mg/mL of polysorbate 80.
31 . The formulation of claim 26 , comprising about 1.30-1.31 mg/mL of citric acid*H2O.
32 . The formulation of claim 26 , comprising about 0.30-0.31 mg/mL sodium citrate dehydrate.